A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: A pilot study

Shatovisha Dey, Natascia Marino, Kanokwan Bishop, Paige N. Dahlgren, Aditi Shendre, Anna Maria Storniolo, Chunyan He, Hiromi Tanaka

Research output: Contribution to journalArticle

Abstract

Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor- and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1 & 2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1 & 2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1 & 2 mutation with age-matched controls of 28 healthy women. The results showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1 & 2 mutation carriers than in age-matched controls from non-obese women (BMI < 30), while there was no association between unaffected BRCA1 & 2 mutation carriers and age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These findings suggest that circulating cfDNA may detect dysfunctional telomeres derived from cells with BRCA1 & 2 mutations and, therefore, its level is associated with breast cancer susceptibility. This pilot study warrants further investigation to elucidate the implication of plasma telomeric cfDNA levels in relation to cancer and obesity.

Original languageEnglish (US)
Pages (from-to)4214-4222
Number of pages9
JournalOncotarget
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Plasma Cells
Mutation
DNA
Telomere
Breast Neoplasms
Tumor Suppressor Genes
Neoplasms
Obesity
Maintenance
Polymerase Chain Reaction

Keywords

  • BRCA1
  • BRCA2
  • Circulating cell-free DNA
  • QPCR
  • Telomere

ASJC Scopus subject areas

  • Oncology

Cite this

A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations : A pilot study. / Dey, Shatovisha; Marino, Natascia; Bishop, Kanokwan; Dahlgren, Paige N.; Shendre, Aditi; Storniolo, Anna Maria; He, Chunyan; Tanaka, Hiromi.

In: Oncotarget, Vol. 9, No. 3, 01.01.2018, p. 4214-4222.

Research output: Contribution to journalArticle

Dey, Shatovisha ; Marino, Natascia ; Bishop, Kanokwan ; Dahlgren, Paige N. ; Shendre, Aditi ; Storniolo, Anna Maria ; He, Chunyan ; Tanaka, Hiromi. / A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations : A pilot study. In: Oncotarget. 2018 ; Vol. 9, No. 3. pp. 4214-4222.
@article{d46dabaf49ab45128c7c27bfe7454d1c,
title = "A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: A pilot study",
abstract = "Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor- and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1 & 2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1 & 2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1 & 2 mutation with age-matched controls of 28 healthy women. The results showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1 & 2 mutation carriers than in age-matched controls from non-obese women (BMI < 30), while there was no association between unaffected BRCA1 & 2 mutation carriers and age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These findings suggest that circulating cfDNA may detect dysfunctional telomeres derived from cells with BRCA1 & 2 mutations and, therefore, its level is associated with breast cancer susceptibility. This pilot study warrants further investigation to elucidate the implication of plasma telomeric cfDNA levels in relation to cancer and obesity.",
keywords = "BRCA1, BRCA2, Circulating cell-free DNA, QPCR, Telomere",
author = "Shatovisha Dey and Natascia Marino and Kanokwan Bishop and Dahlgren, {Paige N.} and Aditi Shendre and Storniolo, {Anna Maria} and Chunyan He and Hiromi Tanaka",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23767",
language = "English (US)",
volume = "9",
pages = "4214--4222",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations

T2 - A pilot study

AU - Dey, Shatovisha

AU - Marino, Natascia

AU - Bishop, Kanokwan

AU - Dahlgren, Paige N.

AU - Shendre, Aditi

AU - Storniolo, Anna Maria

AU - He, Chunyan

AU - Tanaka, Hiromi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor- and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1 & 2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1 & 2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1 & 2 mutation with age-matched controls of 28 healthy women. The results showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1 & 2 mutation carriers than in age-matched controls from non-obese women (BMI < 30), while there was no association between unaffected BRCA1 & 2 mutation carriers and age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These findings suggest that circulating cfDNA may detect dysfunctional telomeres derived from cells with BRCA1 & 2 mutations and, therefore, its level is associated with breast cancer susceptibility. This pilot study warrants further investigation to elucidate the implication of plasma telomeric cfDNA levels in relation to cancer and obesity.

AB - Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor- and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1 & 2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1 & 2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1 & 2 mutation with age-matched controls of 28 healthy women. The results showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1 & 2 mutation carriers than in age-matched controls from non-obese women (BMI < 30), while there was no association between unaffected BRCA1 & 2 mutation carriers and age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These findings suggest that circulating cfDNA may detect dysfunctional telomeres derived from cells with BRCA1 & 2 mutations and, therefore, its level is associated with breast cancer susceptibility. This pilot study warrants further investigation to elucidate the implication of plasma telomeric cfDNA levels in relation to cancer and obesity.

KW - BRCA1

KW - BRCA2

KW - Circulating cell-free DNA

KW - QPCR

KW - Telomere

UR - http://www.scopus.com/inward/record.url?scp=85040170416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040170416&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23767

DO - 10.18632/oncotarget.23767

M3 - Article

AN - SCOPUS:85040170416

VL - 9

SP - 4214

EP - 4222

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -